Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer

Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreatico

Trial Details

NCT ID
NCT07232810
Phase
NA
Sponsor
Minia University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Total Mesopancreas Excision (TMpE)
Locations (sample)
  • Minya, Minya Governorate, Egypt|28.09193,30.75813

Key Eligibility Criteria

  • Age ≥18 years.
  • Patients scheduled to undergo pancreaticoduodenectomy with planned mesopancreatic excision.
  • Histologically confirmed PDAC of the pancreatic head (via endoscopic ultrasound-guided biopsy).
  • Resectable disease per National Comprehensive Cancer Network(NCCN) guidelines (no distant metastases, no arterial involvement \>180°, venous involv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →